COVID-19 immunity may last six months or more

Nov. 13, 2020

People who doctors consider to be recovered from the disease produce virus-fighting antibodies that rapidly evolve in the months following an infection, Howard Hughes Medical Institute Investigator Michel Nussenzweig’s team reported. Six months after infection, those antibodies become both more potent and better at combating mutated versions of the SARS-CoV-2 virus. 

The work, posted as a preprint to bioRxiv.org, has not yet undergone the scientific vetting process known as peer review. But the results suggest that the immune systems of previously infected people might have defenses ready if exposed to the virus again, says Nussenzweig, an immunologist at The Rockefeller University, in New York City. “The really good news is that people who are infected are very unlikely to become sick again for at least six months.” 

The study is critical for scientists trying to understand just how durable people’s immune responses really are, says Leo Stamatatos, an immunologist at the Fred Hutchinson Cancer Research Center, who was not involved with the work. “This work suggests that our bodies can remember SARS-CoV-2 for at least half a year – and probably longer,” he says. “That’s a good thing.” 

Nussenzweig’s team first began recruiting people who had recovered from the COVID-19 disease in April, during the height of the pandemic in New York. At the time, the state’s case count was approaching 10,000 per day, and hospitals faced a deluge of sick people being treated in intensive care units and on ventilators. 

The researchers collected blood from 149 participants and combed it for immune cells that make protective antibodies – those that zero in on the virus and block its entry into cells. “Our idea was that if we’re able to find such neutralizing antibodies, we would know what part of the virus vaccines have to target,” Nussenzweig says. These antibodies might also serve as a blueprint for a new drug – molecules that scientists could purify, produce in mass quantities, and then give to patients to prevent or treat COVID-19. 

Nussenzweig and his colleagues reported their first big find in the journal Nature, in June. One month after infection, all 149 participants had coronavirus-fighting antibodies. “Our results showed that it’s not hard for our immune systems to make effective antibodies to SARS-CoV-2,” says Christian Gaebler, a physician and immunologist in Nussenzweig’s lab. 

The level of these antibodies in the blood was generally low, but their presence in so many people was a bright sign for vaccine development. A vaccine that boosts production of these antibodies could be effective in a broad population of people, the team suggested. 

Nussenzweig’s team took a closer look at the antibodies of six participants and discovered antibodies that were especially effective. Over the last few months, his lab has worked on more than a dozen studies examining two of these exceptional antibodies. Combined in a cocktail, they can protect mice from SARS-CoV-2 infection, the researchers reported in September, in a study now accepted for publication in the Journal of Experimental Medicine. The team has also seen promising results in rhesus macaques. “These antibodies are very, very potent,” Nussenzweig says. His team is planning a Phase 1 clinical trial to test the safety of the antibodies in people. But a potential therapy could still be a long way off. 

In the meantime, “One of the things people worry about a lot is what’s going to happen in six months or a year,” Nussenzweig says. “Are individuals who’ve recovered from COVID-19 still going to be protected?” 

Howard Hughes Medical Institute has the release

More COVID-19 coverage HERE.